The ESMO Congress 2022 was held from 9 to 13 September 2022 in a hybrid format. During this congress, more immunotherapy data were shown in the neoadjuvant setting of head and neck cancer, concomitantly with radiotherapy and updates in first- and second-line recurrent/metastatic disease. Also, this treatment modality is intruding into the field of thyroid cancer. In this report, the most important headlines will be discussed, with comments on the clinical relevance of the different studies.
(Belg J Med Oncol 2022;16(8):404–11)